11060
Identifying and Managing Risk of Disease Progression in Patients with PBC
Date
May 21, 2024
Tracks
Related Products
STUDYING THE THERAPEUTIC BENEFITS OF INNATE IMMUNE STIMULI IN HEPATOCELLULAR CARCINOMA
Beyond personal hygiene, the most impactful public health innovation in human history has been the development of vaccines, which has allowed many scourges of humanity, such as smallpox, to been eradicated or reduced to clinical inconsequentiality…
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
The pancreas is composed of the epithelial and mesenchymal cells. Interaction between the two lineages guides proper formation of the pancreas and modulates progression of pancreatic diseases such as cancer…
CB1 RECEPTOR LOCALIZATION WITHIN THE AFFERENT SPLANCHNIC NEURONS AND ITS IMPACT ON FEEDING BEHAVIOR AND ENERGY EXPENDITURE
BACKGROUND: Our previous research has showed that increased sympathetic nervous activity and decreased cannabinoid receptor 1 (CB1) were associated with increased energy expenditure and weight loss following Roux-en-Y gastric bypass (RYGB) in mice…